Our patients can schedule a COVID-19 vaccination through NYU Langone Health MyChart or the NYU Langone Health app. Learn more about the COVID-19 vaccine. Read our updated information about wearing a mask for your visit.

If you need help accessing our website, call 855-698-9991
Skip to main content
NYU Langone Provider

Kwok-Kin Wong, MD, PhD

NYU Langone Provider
  • Specialty: Medical Oncology
  • Language: English

I immigrated to New York City with my family when I was a child, and I was always interested in a career in medicine. I chose the specialty of lung cancer because I realized that this was an area where I could make the greatest difference. As an immigrant, I wanted to give back to the community and my goal has always been to do my best to elevate the care and treatment options I can give my patients.

At NYU Langone’s Perlmutter Cancer Center, I specialize in treating people with lung cancer, mesothelioma, and other malignant lung conditions. Our team provides outstanding clinical care and also provides the most novel and advanced clinical trial options.

Lung cancer is a complex disease but there are so many different treatments available today. I believe that every patient is different and each person’s needs should be accommodated with a personalized treatment plan. At NYU Langone, we make sure that we understand each patient’s cancer and treatment type through genetic testing to ensure that we provide the best and most effective treatment for that patient.

Through my research, I have provided new insight into the genetic and environmental causes of lung cancer. This has contributed to developing and testing novel lung cancer therapies. I have also identified the role of specific genes that normally control cell growth and survival but become drivers of abnormal cancerous growth in a mutated form. My recent investigations have focused on understanding the sensitivity and resistance to targeted therapies and immunotherapy, with the goal of developing new and better combination therapies for lung cancer patients.

As a physician–scientist, I am excited by the latest advances in cancer research and treatments that have directly improved cancer patient survival. I am fervently committed to expanding cancer research and clinical care with the goal of changing the way we treat lung cancer to make it possible to develop a cure for a majority of patients.

I am a member of the Lung Cancer Research Foundation’s Scientific Advisory Board and also a member of The American Society of Clinical Investigation and the Association of American Physicians, the nation’s oldest honor societies for physician–scientists. I have published more than 250 research studies and my work has been reported in the top peer-reviewed medical and cancer journals. I am the recipient of the 2010 Team Science Award from the American Association of Cancer Research.


Conditions and Treatments

Conditions
  • adenoid cystic carcinoma of the lung
  • lung cancer
  • lung carcinoma
  • malignant mesothelioma
  • mediastinal tumor
  • mesothelioma
  • mucoepidermoid carcinoma of the lung
  • neuroendocrine tumor of the lung
  • non-small cell lung cancer
  • small cell lung cancer
  • solitary fibrous tumor
  • thoracic cancer
  • thymus cancer

Positions
Board Certifications
  • American Board of Internal Medicine (Medical Oncology), 2001
Education and Training
  • Fellowship, Brigham and Womens Hospital, Hematology/Oncology, 2001
  • Residency, Massachusetts General Hospital, Internal Medicine, 1998
  • MD from Columbia University, 1996
  • PhD from Columbia University, 1996

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

  • Aetna
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Agewell
    • Agewell
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
  • ElderPlan
    • ElderPlan
  • Emblem
    • Emblem Select Care Exchange
  • Empire Blue Cross Blue Shield
    • Empire Blue Cross Blue Shield EPO
    • Empire Blue Cross Blue Shield HMO
    • Empire Blue Cross Blue Shield HealthPlus
    • Empire Blue Cross Blue Shield HealthPlus Essential
    • Empire Blue Cross Blue Shield Indemnity
    • Empire Blue Cross Blue Shield MediBlue
    • Empire Blue Cross Blue Shield POS
    • Empire Blue Cross Blue Shield PPO
  • Fidelis
    • Fidelis Child Health
    • Fidelis Essential
    • Fidelis Exchange
    • Fidelis Medicaid
    • Fidelis Medicare
  • GHI
    • GHI CBP
  • HIP
    • HIP Access I
    • HIP Access II
    • HIP Child Health
    • HIP EPO/PPO
    • HIP Essential
    • HIP HMO
    • HIP Medicaid
    • HIP Medicare
    • HIP POS
  • HealthSmart
    • HealthSmart (WTC)
View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

  • Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

    Learn More
View All Research Studies (1)

  • Briere, David M; Li, Shuai; Calinisan, Andrew; Sudhakar, Niranjan; Aranda, Ruth; Hargis, Lauren; Peng, David H; Deng, Jiehui; Engstrom, Lars D; Hallin, Jill; Gatto, Sole; Fernandez-Banet, Julio; Pavlicek, Adam; Wong, Kwok-Kin; Christensen, James G; Olson, Peter

    Molecular cancer therapeutics. 2021 Jun ; 20(6):975-985

  • Wu, Zhong; Zhou, Jin; Zhang, Xiaoyang; Zhang, Zhouwei; Xie, Yingtian; Liu, Jie Bin; Ho, Zandra V; Panda, Arpit; Qiu, Xintao; Cejas, Paloma; Cañadas, Israel; Akarca, Fahire Goknur; McFarland, James M; Nagaraja, Ankur K; Goss, Louisa B; Kesten, Nikolas; Si, Longlong; Lim, Klothilda; Liu, Yanli; Zhang, Yanxi; Baek, Ji Yeon; Liu, Yang; Patil, Deepa T; Katz, Jonathan P; Hai, Josephine; Bao, Chunyang; Stachler, Matthew; Qi, Jun; Ishizuka, Jeffrey J; Nakagawa, Hiroshi; Rustgi, Anil K; Wong, Kwok-Kin; Meyerson, Matthew; Barbie, David A; Brown, Myles; Long, Henry; Bass, Adam J

    Nature genetics. 2021 Jun ; 53(6):881-894

  • Deng, Jiehui; Thennavan, Aatish; Dolgalev, Igor; Chen, Ting; Li, Jie; Marzio, Antonio; Poirier, John T; Peng, David; Bulatovic, Mirna; Mukhopadhyay, Subhadip; Silver, Heather; Papadopoulos, Eleni; Pyon, Val; Thakurdin, Cassandra; Han, Han; Li, Fei; Li, Shuai; Ding, Hailin; Hu, Hai; Pan, Yuanwang; Weerasekara, Vajira; Jiang, Baishan; Wang, Eric S; Ahearn, Ian; Philips, Mark; Papagiannakopoulos, Thales; Tsirigos, Aristotelis; Rothenberg, Eli; Gainor, Justin; Freeman, Gordon J; Rudin, Charles M; Gray, Nathanael S; Hammerman, Peter S; Pagano, Michele; Heymach, John V; Perou, Charles M; Bardeesy, Nabeel; Wong, Kwok-Kin

    Nature cancer. 2021 May ; 2(5):503-514

Read All Publications (292)

Related News